Concepedia

Bryan K. Sorensen

BK

Statistics

Publications

22

Citations

829

H-Index

17

Active since

1993

Affiliations

Abbott Fund(Current)

Abbott (United Kingdom)

Karo Pharma (Sweden)

AbbVie (United States)

Bryan K. Sorensen is an author at Abbott Fund specializing in drug discovery, pharmacology, and medicinal chemistry.

Publications per year

1993–2017

22

Publications

22

2,4-Diarylpyrrolidine-3-carboxylic AcidsPotent ET<sub>A</sub> Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722

Martin Winn, Thomas W von Geldern, Terry J. Opgenorth et al. · Journal of Medicinal Chemistry · 1996 · 113 citations · Full text

, , +17

Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 4. Side Chain Conformational Restriction Leads to ET<sub>B</sub> Selectivity

Thomas W von Geldern, Andrew S. Tasker, Bryan K. Sorensen et al. · Journal of Medicinal Chemistry · 1999 · 90 citations · Full text

, , +17

Discovery and Metabolic Stabilization of Potent and Selective 2-Amino-<i>N</i>-(adamant-2-yl) Acetamide 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors

Jeffrey J. Rohde, Marina Pliushchev, Bryan K. Sorensen et al. · Journal of Medicinal Chemistry · 2006 · 77 citations · Full text

, , +16

Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors

Bryan K. Sorensen, Martin Winn, Jeff Rohde et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 64 citations · Full text

, , +3

Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases

Steve Fidanze, Scott Erickson, Gary T. Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 56 citations · Full text

, , +14

1–5 of 22